e assessed the pathophysiology of Brugada syndrome (BrS) in primary cardiomyocytes obtained from a 64-year-old male patient. At age 54 the patient had experienced syncope and presented with type 1 ST-segment elevation on the surface ECG during a febrile infection. Whole exome sequencing was performed to identify the genetic basis of BrS, yielding 88 325 variants in the index patient. Filtering out noncoding, synonymous, and benign variants yielded 11 nonsynonymous variants. In silico analyses predicted potential pathogenicity for 4 out of 11 variants, located in genes encoding for SNTB2 (β-2-syntrophin), obscurin, the α-1H subunit of the voltage-dependent T-type calcium channel, and LRP1 (low-density lipoprotein receptor-related protein-1). The present work represents a candidate gene study, focusing on the role of SNTB2 in BrS pathophysiology. Potential mechanistic contribution of other variants to BrS, for example through interaction between obscurin and Na v 1.5 via ankyrin, remains to be investigated. Syntrophins interact directly with the cardiac Na v 1.5 channel at a binding domain consisting of an SIV (Ser-Ile-Val) motif.
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1,2 A BrS-associated SCN5A missense mutation in the SIV motif decreased Na v 1.5 surface expression and Na + currents in human embryonic kidney (HEK298T) cells. 3 In the BrS patient, direct sequencing confirmed the presence of a heterozygous SNTB2-N167K mutation located in the Na v 1.5 binding region. Sanger sequencing was extended to an independent cohort of 115 unrelated patients with BrS. No SNTB2 mutations were detected in these patients, reflecting low frequency of the mutated allele.
To assess the molecular pathophysiology of BrS associated with SNTB2-N167K, right atrial tissue samples were obtained from the index patient during coronary artery bypass grafting at age 64. Reduced cardiac abundance of SNTB2 and Na v 1.5 protein in the BrS patient is illustrated by immunoblots of right atrial protein lysates of the index patient in comparison with 3 unrelated control subjects undergoing open heart surgery for coronary artery bypass grafting (Figure [A] ).
Cardiac myocytes were isolated from right atrial samples and subjected to electrophysiological recordings to assess functional consequences of the PDZ domain mutation in SNTB2 (Figure [B] ). Peak I Na density at −50 mV was reduced by 86.7% in the BrS patient (n=10) compared with control subjects (n=8 cells obtained from N=3 individuals; P=0.0008; Figure [C] ). Current reduction was accompanied by a depolarizing shift of the half-maximal activation voltage from −57.9±1.7 mV (probands; n/N=8/3) to −43.5±1.0 mV (BrS patient; n=5; P<0.0001). In addition to peak I Na , the late sodium current (I Na-L ) has been implicated in arrhythmogenesis and antiarrhythmic therapy and was modulated by interaction with α-1-syntrophin in vitro. 4 ,5 I Na-L density was reduced by 72.1% (n=8) in the BrS patient compared with non-affected controls (n/N=8/3; P=0.049; Figure [D (115±14.6 ms; n=6) compared with 217±11.6 ms in probands (n/N=8/6; P=0.0003; Figure [E and F] ). APD at 50% of repolarization (APD 50 ) was similarly shortened.
To further elucidate the cellular mechanism underlying SNTB2-N167K-associated BrS, wild-type (WT), or mutant SNTB2 were coexpressed with human Na v 1.5 in HEK293T cells. Colocalization of WT SNTB2 and Na v 1.5 ( Figure [G] ) was not observed when SNTB2-N167K was expressed (Figure [H] ), suggesting defective interaction between the proteins. Reduced sodium current upon coexpression of Na v 1.5 with WT SNTB2 and SNTB2-N167K (to mimic heterozygous conditions in the index patient) or with SNTB2-N167K alone (to model homozygous conditions) was recapitulated in the Xenopus oocyte expression system ( Figure [I through K] ). Significant Na + current reduction in homozygous conditions and similar Na + current levels in oocytes mimicking the heterozygous situation suggest a dominant-negative effect of mutant SNTB2-N167K on its WT counterpart. Sodium currents produced by coexpression of Na v 1.5 and SNTB2-N167K (−11.0±2.5 µA; n=7) were 58.2% lower compared with coexpression of Na v 1.5 with WT SNTB2 (−26.2±3.9 µA; n=5; P=0.01). Physical interaction between WT SNTB2 and Na v 1.5 was finally demonstrated by coimmunoprecipitation of both proteins (Figure [L] ). By contrast, mutant SNTB2-N167K was not isolated when Na v 1.5 was immunopurified (and vice versa), confirming loss of SNTB2-Na v 1.5 interaction caused by the BrS-associated mutation.
Limitations arise from the use of atrial cardiomyocytes because ventricular tissue was not available. Nonetheless, functional and regulatory similarities between atrial and ventricular I Na indicate that the findings of the present work may be extrapolated to ventricular electrophysiology. Further limitations include the lack of functional rescue or knockin experiments (potentially including genome-edited induced pluripotent stem cell (iPSC)-derived cardiomyocytes) that would be required to establish the causal nature of the SNTB2 variant. In addition, the study represents a report from a single patient without appropriately matched control cells. Further studies are needed to validate this hypothesisdriven study in a larger number of BrS patients and appropriate controls.
In conclusion, reduced I Na underlying BrS was functionally demonstrated in native human cardiomyocytes. SNTB2 was identified as a novel gene associated with BrS. Mutation of SNTB2 reduced Na v 1.5 current through defective functional Na v 1.5-SNTB2 interaction (Figure [M] ). Figure 1 Continued. L, Coimmunoprecipitation (IP) of Na v 1.5 with SNTB2 in HEK293T cells. Anti-FLAG antibodies detecting SNTB2-FLAG and anti-HA antibodies binding Na v 1.5-HA were used for IP and immunoblotting (IB), and vice versa. Coprecipitation of SNTB2 and Na v 1.5 was not observed in the presence of SNTB2-N167K. M, Cellular mechanism of BrS associated with SNTB2-N167K-mutation. Mutation of SNTB2 in a BrS patient disrupts regional and functional interaction with Na v 1.5 in cardiac myocytes, resulting in reduced cardiac sodium current compared with a healthy subject. For scatter dot plots, center line shows mean, error bars indicate SEM (*P<0.001 and †P<0.05).
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